Literature DB >> 2690940

Cross-linking of a monomeric 39/34-kDa dispase fragment of von Willebrand factor (Leu-480/Val-481-Gly-718) to the N-terminal region of the alpha-chain of membrane glycoprotein Ib on intact platelets with bis(sulfosuccinimidyl) suberate.

R K Andrews1, J J Gorman, W J Booth, G L Corino, P A Castaldi, M C Berndt.   

Abstract

A 39/34-kilodalton (kDa) monomeric dispase fragment of von Willebrand factor (vWF) has been purified by heparin affinity chromatography. Detailed structural analysis of the individual 39- and 34-kDa fragments indicated that they had identical amino acid sequences extending from Leu-480/Val-481 to Gly-718 with an intramolecular disulfide bond between Cys-509 and Cys-695. In addition to the binding site for heparin, the 39/34-kDa fragment also contained binding sites for collagen and for platelet membrane glycoprotein (GP) Ib. Unlike native vWF, the 39/34-kDa fragment bound to GP Ib without the requirement for a modulator but showed increased binding in the presence of botrocetin. The 39/34-kDa vWF fragment was cross-linked to intact human platelets by using the membrane-impermeable, homobifunctional cross-linking reagent bis(sulfosuccinimidyl) suberate. Two distinct cross-linked species of similar molecular weight (220/200 kDa, nonreduced; 190/175 kDa, reduced) were identified by SDS-polyacrylamide gel electrophoresis and autoradiography, consistent with the cross-linking of the 125I-labeled 39/34-kDa vWF fragment to GP Ib. The formation of these cross-linked species was enhanced 1.5-2.5-fold in the presence of the modulator botrocetin. The platelet membrane protein involved in cross-linking was shown unequivocally to be GP Ib since (i) neither cross-linked species was formed with Bernard-Soulier syndrome platelets, which genetically lack the GP Ib-IX complex, (ii) both cross-linked species were specifically immunoprecipitated by anti-GP Ib polyclonal and monoclonal antibodies, and (iii) the formation of the cross-linked species was completely inhibited only by those anti-GP Ib-IX complex monoclonal antibodies that inhibited vWF-GP Ib-IX complex interaction. Proteolysis of cross-linked platelets with endoproteinase Lys-C, which preferentially cleaves off the N-terminal peptide domain on the alpha-chain of GP Ib, indicated that the 39/34-kDa vWF fragment was cross-linked exclusively to this region of the GP Ib-IX complex.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690940     DOI: 10.1021/bi00447a010

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

Review 1.  Platelet GP Ib/IX/V complex: physiological role.

Authors:  J Rivera; M L Lozano; J Corral; R González-Conejero; C Martínez; V Vicente
Journal:  J Physiol Biochem       Date:  2000-12       Impact factor: 4.158

2.  The Von Willebrand Factor A1-Collagen III Interaction Is Independent of Conformation and Type 2 Von Willebrand Disease Phenotype.

Authors:  Venkata R Machha; Alexander Tischer; Laurie Moon-Tasson; Matthew Auton
Journal:  J Mol Biol       Date:  2016-11-24       Impact factor: 5.469

Review 3.  Von Willebrand's disease.

Authors:  I M Nilsson; S Lethagen
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

4.  Thrombotic thrombocytopenic purpura: reducing the risk?

Authors:  Michael C Berndt; Robert K Andrews
Journal:  J Clin Invest       Date:  2011-01-25       Impact factor: 14.808

5.  Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor.

Authors:  J Ware; J A Dent; H Azuma; M Sugimoto; P A Kyrle; A Yoshioka; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

6.  Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences.

Authors:  A M Randi; I Rabinowitz; D J Mancuso; P M Mannucci; J E Sadler
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

7.  Delimiting the autoinhibitory module of von Willebrand factor.

Authors:  W Deng; K M Voos; J K Colucci; E R Legan; E A Ortlund; P Lollar; R Li
Journal:  J Thromb Haemost       Date:  2018-08-16       Impact factor: 5.824

8.  A low-affinity, low-molecular-mass endothelin-A receptor in neonatal rat heart.

Authors:  E A Woodcock; S L Land; R K Andrews; M Linsenmeyer; D M Woodcock
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

9.  von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.

Authors:  I Rabinowitz; E A Tuley; D J Mancuso; A M Randi; B G Firkin; M A Howard; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.